Evidence map›Paper›PMID 35468807›Full record

ArticleTrials2022

The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments.

Jason S Haukoos, Sarah E Rowan, James W Galbraith, Richard E Rothman, Yu-Hsiang Hsieh, Emily Hopkins, Rachel A Houk, Matthew F Toerper, Kevin F Kamis, Jake R Morgan and 8 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04003454 (The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04003454 nacompletednot on this map

The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV Trial

TypeinterventionalSponsorDenver Health and Hospital AuthorityRan2019 to 2024Enrolled147,533ConditionsHepatitis CArmsHCV Screening
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Use of EpicClinical trials (London, England) · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

Jason S HaukoosDepartment of Emergency Medicine, Denver Health Medical Center and University of Colorado School of Medicine, 777 Bannock Street, Mail Code 0108, Denver, CO, 80204, USA. jason.haukoos@dhha.org.ORCID http://orcid.org/0000-0001-7784-6811
Sarah E RowanDivision of Infectious Diseases, Denver Health Medical Center and University of Colorado School of Medicine, Denver, CO, USA.
James W GalbraithDepartment of Emergency Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Richard E RothmanDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD, USA.
Yu-Hsiang HsiehDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD, USA.
Emily HopkinsDepartment of Emergency Medicine, Denver Health Medical Center and University of Colorado School of Medicine, 777 Bannock Street, Mail Code 0108, Denver, CO, 80204, USA.
Rachel A HoukDepartment of Informational Technology, Denver Health, Denver, CO, USA.
Matthew F ToerperDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD, USA.
Kevin F KamisPublic Health Institute at Denver Health, Denver, CO, USA.
Jake R MorganDepartment of Health Law, Policy, and Management, Boston University School of Public Health, Boston, MA, USA.
Benjamin P LinasCenter for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, Boston, MA, USA.
Alia A Al-TayyibDepartment of Epidemiology, Colorado School of Public Health, Aurora, CO, USA.
Edward M GardnerDivision of Infectious Diseases, Denver Health Medical Center and University of Colorado School of Medicine, Denver, CO, USA.
Michael S LyonsDepartment of Emergency Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA.
Allison L SabelDepartment of Patient Safety and Quality, Denver Health, Denver, CO, USA.
Douglas A E WhiteDepartment of Emergency Medicine, Highland Hospital, Alameda Health System, Oakland, CA, USA.
David L WylesDivision of Infectious Diseases, Denver Health Medical Center and University of Colorado School of Medicine, Denver, CO, USA.
DETECT Hep C Trials Investigators
Denver Health Medical Center · USColorado School of Public Health · USJohns Hopkins University · USBoston University · USUniversity of Cincinnati · USAlameda Health System · USJackson Memorial Hospital · US

Funding

The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV TrialR01DA042982 · NIDA · DENVER HEALTH AND HOSPITAL AUTHORITY · PI HAUKOOS, JASON, ROWAN, SARAH ELIZABETH · 2018 to 2022
$3.0M
NIDA NIH HHS R01 DA042982NIDA NIH HHS R01DA042982
6 · The paper itself

Abstract

backgroundEarly identification of HCV is a critical health priority, especially now that treatment options are available to limit further transmission and provide cure before long-term sequelae develop. Emergency departments (EDs) are important clinical settings for HCV screening given that EDs serve many at-risk patients who do not access other forms of healthcare. In this article, we describe the rationale and design of The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial.

methodsThe DETECT Hep C Screening Trial is a multi-center prospective pragmatic randomized two-arm parallel-group superiority trial to test the comparative effectiveness of nontargeted and targeted HCV screening in the ED with a primary hypothesis that nontargeted screening is superior to targeted screening when identifying newly diagnosed HCV. This trial will be performed in the EDs at Denver Health Medical Center (Denver, CO), Johns Hopkins Hospital (Baltimore, MD), and the University of Mississippi Medical Center (Jackson, MS), sites representing approximately 225,000 annual adult visits, and designed using the PRECIS-2 framework for pragmatic trials. When complete, we will have enrolled a minimum of 125,000 randomized patient visits and have performed 13,965 HCV tests. In Denver, the Screening Trial will serve as a conduit for a distinct randomized comparative effectiveness trial to evaluate linkage-to-HCV care strategies. All sites will further contribute to embedded observational studies to assess cost effectiveness, disparities, and social determinants of health in screening, linkage-to-care, and treatment for HCV. DISCUSSION: When complete, The DETECT Hep C Screening Trial will represent the largest ED-based pragmatic clinical trial to date and all studies, in aggregate, will significantly inform how to best perform ED-based HCV screening.

trial registrationClinicalTrials.gov ID: NCT04003454 . Registered on 1 July 2019.

Indexed as

Hepatitis CAdultEmergency Service, HospitalEquivalence Trials as TopicHepacivirusHumansMass ScreeningMulticenter Studies as TopicPragmatic Clinical Trials as TopicProspective StudiesRandomized Controlled Trials as TopicTreatment OutcomeClinical trialComparative effectivenessEmergency departmentHCVHepatitis CImplementationMethodsPragmatic trialPreventionRandomized trialScreeningTesting

Identifiers

PMID35468807
PMCPMC9036509
OpenAlexW4225261154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.